Viking's Weight-Loss Pill Shows Lower Results
Viking Therapeutics' oral VK2735 achieved up to 12.2% weight loss in a Phase 2 trial, which was below expectations. It is safe, well-tolerated, and has mild gastrointestinal effects.
/ 20 items
Viking Therapeutics' oral VK2735 achieved up to 12.2% weight loss in a Phase 2 trial, which was below expectations. It is safe, well-tolerated, and has mild gastrointestinal effects.
Lilly's new oral GLP-1, orforglipron, shows 11-12.4% weight loss in late-stage trial, short of Zepbound and Wegovy. Easier to produce and distribute than injectables, it targets wider patient access. FDA submission this year.